1. Home
  2. BY vs TSHA Comparison

BY vs TSHA Comparison

Compare BY & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BY

Byline Bancorp Inc.

HOLD

Current Price

$30.30

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$4.57

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BY
TSHA
Founded
1914
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.2B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
BY
TSHA
Price
$30.30
$4.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
9
Target Price
$33.50
$10.56
AVG Volume (30 Days)
131.5K
2.2M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
1.55%
N/A
EPS Growth
5.09
62.50
EPS
2.89
N/A
Revenue
N/A
$8,333,000.00
Revenue This Year
$17.06
N/A
Revenue Next Year
$2.84
N/A
P/E Ratio
$10.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.63
$1.13
52 Week High
$33.89
$6.02

Technical Indicators

Market Signals
Indicator
BY
TSHA
Relative Strength Index (RSI) 37.29 48.07
Support Level $28.44 $4.39
Resistance Level $31.24 $5.16
Average True Range (ATR) 0.76 0.19
MACD -0.18 0.01
Stochastic Oscillator 16.21 65.06

Price Performance

Historical Comparison
BY
TSHA

About BY Byline Bancorp Inc.

Byline Bancorp Inc is the holding company for Byline Bank, a full-service commercial bank serving small-and-medium sized businesses, financial sponsors, and consumers. The company offers a broad range of banking products and services to small and medium sized businesses, commercial real estate and online account opening to consumer and business. Also provide trust and wealth management services to its customers. In addition to traditional commercial banking business, company provide small ticket equipment leasing solutions through Byline Financial Group, a wholly-owned subsidiary of Byline Bank.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Share on Social Networks: